Table 1.
Patient characteristics of transfused and non-transfused patients (in the first 60 days after IT start).
| total(N = 55), n (%) | RBC transfusion (N = 15), n (%) | no RBC transfusion (N = 40), n (%) | p-valuea | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean | 62 | 56 | 65 | 0.059* |
| Range | 34-90 | 34-82 | 37-90 | |
| Elderly (>70) | 15 (27.3) | 2 (13.3) | 13 (32.5) | 0.192 |
| Gender | 0.184 | |||
| Male | 39 (70.9) | 13 (86.7) | 26 (65.0) | |
| Female | 16 (29.1) | 2 (13.3) | 14 (35.0) | |
| ECOG | 1.000 | |||
| 0-1 | 35 (63.6) | 9 (60.0) | 26 (65.0) | |
| ≥2 | 17 (30.9) | 5 (33.3) | 12 (30.0) | |
| Primarius | 0.414 | |||
| Lung | 19 (34.5) | 2 (13.3) | 17 (42.5) | |
| Skin | 7 (12.7) | 2 (13.3) | 5 (12.5) | |
| Head neck | 10 (18.2) | 4 (26.7) | 6 (15.0) | |
| Urogenital | 5 (9.1) | 2 (13.3) | 3 (7.5) | |
| CUP | 4 (7.3) | 1 (6.7) | 3 (7.5) | |
| Breast | 3 (5.5) | 1 (6.7) | 2 (5.0) | |
| Others | 7 (12.7) | 3 (20.0) | 4 (10.0) | |
| One drug Immunotherapy | 0.011 | |||
| Atezolizumab | 8 (14.5) | 2 (13.3) | 6 (15.0) | |
| Pembrolizumab/Nivolumab | 34 (61.8) | 6 (40.0) | 28 (70.0) | |
| Ipilimumab | 1 (1.8) | 0 | 1 (2.5) | |
| Two drug immunotherapy | ||||
| Nivolumab+Ipilimumab | 12 (21.8) | 7 (46.7) | 5 (12.5) | |
| Additional chemotherapy | 15 (27.3) | 3 (20.0) | 12 (30.0) | 0.461 |
| Additional radiotheraphy | 11 (20.0) | 3 (20.0) | 8 (20.0) | 1.000 |
| Line of therapy | 0.016 | |||
| 1 | 14 (25.5) | 0 | 14 (35.0) | |
| 2 | 15 (27.3) | 4 (26.7) | 11 (27.5) | |
| 3 | 13 (23.6) | 7 (46.7) | 6 (15.0) | |
| 4 | 5 (9.1) | 2 (13.3) | 3 (7.5) | |
| ≥5 | 8 (14.5) | 2 (13.3) | 6 (15.0) | |
| Mean | 2.7 | 3.4 | 2.5 | |
| Number of organs with metastasis | 0.912* | |||
| Mean | 1.7 | 1.7 | 1.8 | |
| LDH | 0.441* | |||
| Mean | 317 | 457 | 262 | |
(a) was calculated using Fisher's exact/ (*) Wilcoxon. RBC, red blood cell; CUP, cancer of unkown primary.